Androgen Drug Class List

Drugs in Drug Class: Androgen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-001	Sep 28, 2018		RX	Yes	Yes	10,238,662		Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-001	Sep 28, 2018		RX	Yes	Yes	10,478,560		Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-002	Sep 28, 2018		RX	Yes	Yes	10,357,609		Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes	11,446,440		Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes	9,744,302		Y

Market dynamics and patent landscape for drugs in the Androgen class

Last updated: April 24, 2026

What defines the androgen drug market and how does demand move?

The “androgen” drug class spans testosterone and synthetic anabolic-androgenic steroids (AAS) and includes agents used for hypogonadism and other androgen-responsive indications (including prostate cancer, depending on product and regulatory label). Market structure is shaped by (1) endocrine replacement demand, (2) oncology androgen-deprivation and anti-androgen standards of care, and (3) payer and guideline adherence around preferred formulations.

Demand drivers and demand volatility

Key demand inputs that move androgen-related sales:

• Hypogonadism diagnosis and testosterone prescribing rates (primary demand pool for replacement and related therapeutic areas).
• Switching within replacement options (short-acting vs long-acting injections, gels, patches, oral forms).
• Oncology regimen shifts (use of androgen pathway agents in prostate cancer changes with guideline updates and trial results).
• Safety communications and utilization management (class-wide labeling changes and risk monitoring can depress initiation and shift persistence).
• Patent and formulation cliffs (post-patent generic uptake can materially reduce branded revenue; new formulations extend market access).

Revenue dynamics: branded-to-generic transition dominates

Across androgen products, the economic pattern is consistent:

• Branded testosterone formulations face competitive pressure when composition-of-matter and key formulation patents expire.
• Late-cycle entrants often rely on extended-release technologies, prodrug or ester strategies, device-enabled delivery, or new salt/solvate forms that target exclusivity.
• Biosimilar dynamics apply for products that meet biosimilarity frameworks (less central for classic testosterone generics, more relevant where biologics or complex manufacturing defines exclusivity boundaries).

Pricing and access

Commercial dynamics commonly reflect:

• Formulary preference for specific delivery systems (e.g., gels vs injectables) based on cost, administration burden, and patient adherence.
• Utilization management (prior authorization, step therapy) especially where diagnosis criteria are strict.
• Consolidation of contracts after generic entry, compressing branded pricing.

Which androgen patents most often control exclusivity and what do they cover?

Androgen exclusivity is governed by a mix of:

• Composition-of-matter (CoM) claims (new androgen entities, esters, prodrugs, salts, and solid forms).
• Formulation patents (controlled release, transdermal penetration enhancers, long-acting depot matrices).
• Method-of-use patents (specific dosing regimens, patient populations, combination therapy).
• Device and delivery system patents (injector systems, transdermal systems with specific release characteristics).
• Process patents (manufacturing improvements that can matter for regulatory filing and litigation posture).
• Regulatory exclusivity (data exclusivity and marketing exclusivity where applicable in given jurisdictions).

Patent claim “hooks” that commonly sustain exclusivity

Across androgen product portfolios, the strongest late-life protection typically comes from:

• Long-acting depot technologies (injection formulations that sustain plasma exposure over extended intervals).
• Transdermal delivery systems (membrane, adhesive, and skin permeation design that improves pharmacokinetics).
• Novel ester/prodrug scaffolds that change release and metabolic profile while maintaining androgen activity.

Where is the patent landscape concentrated: molecules, formulations, or indications?

The androgen patent landscape is concentrated in formulations and sustained-release technologies for long-term market share retention. CoM still matters where new chemical entities or distinct prodrug/ester strategies are protected, but many brands rely on:

• Drug product exclusivity to preserve differentiation when generic CoM is vulnerable.
• Method-of-use and regimen claims to resist “skinny labels” or to shape biosimilar/generic switching.

Structural map of androgen IP by product type

Product type	Typical dominant IP category	Why it persists through generic cycles
Testosterone injections (long-acting esters)	Formulation + process	Release kinetics are formulation-dependent; depot behavior changes can require “work-around”
Testosterone gels/patches	Formulation + delivery system	Skin penetration and rate control can be protected and require device- or formulation-specific development
Oral and novel androgen prodrugs	CoM + formulation	Chemical scaffold and absorption mechanics can be harder to replicate without new patents

How do biosimilar/generic entry patterns affect androgen pricing and market share?

Generic entry mechanics

When patents covering the key CoM or formulation claims expire, follow-on entrants typically compete on:

• Wholesale acquisition cost (WAC) discounting,
• Formulary placement, and
• Switching campaigns by payers and pharmacy benefit managers.

Competitive outcomes

Post-exclusivity results typically follow:

• Rapid branded margin compression for products where generics match the same delivery mode and dosing schedule.
• Slower substitution where brands have differentiation via prolonged release or patient-tolerability advantages supported by labeling and pharmacokinetic data.
• Fragmented market across delivery modalities that remain partially insulated by access and patient preference.

What does the androgen patent landscape imply for near-term R&D risk?

R&D risk is highest in projects that attempt to copy:

• The same delivery system (same release mechanism and kinetics),
• The same ester/prodrug scaffold, or
• The same method-of-use population and dosing regimen already claimed.

The risk decreases when development targets:

• Different release kinetics,
• A distinct molecular scaffold with separate CoM protection,
• A different clinical positioning (label indication, line of therapy, or combination strategy) that can be supported by new clinical data.

Typical “risk zones” in androgen portfolios

Development area	High litigation risk	Lower risk strategies
Long-acting depot injections	Replicating known depot matrices or kinetics	New sustained-release chemistry, different depot carrier design
Transdermal systems	Matching penetration and release rate	Distinct delivery membrane/adhesive system
Indication expansions	Re-using already claimed regimens	New patient subsets, dosing schedules, or combinations supported by outcomes

How do patents interact with clinical guidelines and prescribing behavior?

Clinical guidelines drive prescribing, but patents drive commercial timing. In androgen therapy:

• When guidelines favor a specific molecule and formulation (e.g., a preferred long-acting injection or transdermal system), branded products may maintain volume even as partial generic pressure emerges.
• When guideline shifts occur (e.g., changes in prostate cancer androgen pathway treatment pathways), patent portfolios in oncology androgen signaling agents can be decisive. For androgen class products used in replacement, diagnosis rates and safety monitoring often dominate.

What are the actionable market scenarios implied by the androgen patent cycle?

Scenario 1: Post-patent decline without new differentiation

• Branded declines when generic entrants can match the same delivery modality and dosing without infringing key formulation or CoM claims.
• Clinical switching accelerates if payers impose step therapy and if alternative formulations are interchangeable at the provider level.

Scenario 2: Branded resilience through formulation differentiation

• Branded sustains share when differentiation hinges on long-acting delivery performance or device-dependent administration.
• Litigation and “design-around” costs delay full substitution.

Scenario 3: Portfolio re-risking through new IP layering

• Brands extend reach by stacking new patents that cover incremental changes: improved delivery, new solid forms, new dosing interval, or specific patient populations.

Key Takeaways

• The androgen market is primarily driven by hypogonadism prescribing and formulation switching, with oncology androgen pathway standards of care shaping additional demand.
• Exclusivity is most often preserved through formulation, delivery system, and long-acting kinetics patents, not only CoM.
• Competitive outcomes after patent expiry depend on whether entrants can match release kinetics and delivery performance while avoiding formulation- and device-level IP.
• Highest R&D litigation risk sits in “copycat” development of existing esters/prodrugs and delivery platforms; lower risk comes from distinct release chemistry, scaffolds, or clinically supported regimen repositioning.

FAQs

1. Which IP categories most frequently determine androgen brand survival after first CoM expiry?
   Formulation, delivery system, and method-of-use claims tied to sustained plasma exposure and regimen-specific outcomes.

2. Why do long-acting and transdermal androgen products face different substitution speeds than short-acting injectables?
   Because sustained-release behavior and skin penetration rates can be protected and are harder to replicate without infringing formulation and device-level claims.

3. How do payer controls affect androgen market share during generic entry?
   Prior authorization and step therapy accelerate switching when payer formularies prefer lower-cost equivalents, compressing branded volume.

4. What R&D design choices reduce infringement risk in androgen development?
   Choose distinct scaffolds or sustained-release mechanisms, avoid matching the same delivery kinetics, and anchor any new regimen in new clinical evidence.

5. What market signals predict a coming branded decline in androgen therapy?
   Imminent expiration of key formulation and delivery patents, combined with payer formulary updates and the arrival of multiple equivalent follow-on products.

References

[1] Bloomberg Law. Patent and market intelligence for drug exclusivity and litigation (accessed for general framework).
[2] U.S. FDA. Drug approval packages and labeling for testosterone products and related androgen agents (accessed for general regulatory context).
[3] EMA. European public assessment reports and product information for testosterone and androgen products (accessed for general regulatory context).